Verastem, Inc. Supports Worldwide Rare Disease Day On February 28, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced its support of the rare disease awareness events being held globally. Verastem’s lead compound targeting cancer stem cells, VS-6063, is currently in the registration-directed COMMAND study and has been granted orphan drug designation in the U.S. and E.U. for use in mesothelioma.

Help employers find you! Check out all the jobs and post your resume.